Array BioPharma Inc (ARRY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Array BioPharma Inc (ARRY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10123
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Array BioPharma Inc (Array) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of targeted small-molecule drugs indicated for the treatment of cancer and inflammatory diseases. The company’s most advanced wholly-owned clinical stage drugs include binimetinib, a MEK inhibitor for cancer; encorafenib, a BRAF inhibitor for cancer; selumetinib, MEK inhibitor for various cancers and ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy, (LMNA-DCM). It has several partner programs in collaborations with AstraZeneca; Roche Holding; Aslan Pharmaceuticals; Genentech; VentiRx Pharmaceuticals; Eli Lilly; Cascadian Therapeutics; and Loxo Oncology. Array is headquartered in Boulder, Colorado, the US.

Array BioPharma Inc (ARRY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Array BioPharma Acquires Encorafenib from Novartis Pharma 13
Venture Financing 15
Loxo Oncology Raises US$10 Million In Venture Financing 15
Partnerships 16
Array BioPharma Enters into Agreement with Pfizer 16
Amgen and Array BioPharma Enter into Agreement 17
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 18
Array BioPharma Enters into Agreement with Merck 19
Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 20
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 21
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 22
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 23
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 24
Licensing Agreements 25
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 25
Ono Pharma Enters into Licensing Agreement with Array BioPharma 26
Mirati Therapeutics Exercises Option For Licensing Agreement With Array BioPharma 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 29
Loxo Oncology Amends Licensing Agreement With Array BioPharma 30
Equity Offering 32
Array Biopharma Plans to Raise up to USD125 Million in Public Offering of Shares 32
Yarra Therapeutics Spins Out from Array BioPharma 33
Array BioPharma Raises USD258.7 Million in Public Offering of Shares 34
Array BioPharma Raises USD132.3 Million in Public Offering of Shares 36
Array Biopharma Announces Public Offering Of Shares For US$75 Million 38
Array BioPharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$10 Million 39
Array BioPharma Completes Public Offering Of Common Stock For US$60 Million 41
Debt Offering 43
Array BioPharma Raises USD10 Million in Private Placement of 5% Notes Due 2017 43
Array BioPharma Completes Public Offering Of Notes Due 2020 For US$132 Million 44
Asset Transactions 46
Accuratus Lab Services Acquires CMC Operation from Array BioPharma 46
Array BioPharma Inc – Key Competitors 47
Array BioPharma Inc – Key Employees 48
Array BioPharma Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Oct 30, 2018: Array BioPharma reports financial results for the first quarter of fiscal 2019 50
Aug 14, 2018: Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2018 52
May 09, 2018: Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 56
Feb 06, 2018: Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018 59
Oct 31, 2017: Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2018 61
Aug 09, 2017: Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 64
May 10, 2017: Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017 68
Feb 09, 2017: Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017 70
Corporate Communications 74
Apr 27, 2017: Shalini Sharp Joins Array BioPharma Board of Directors 74
Legal and Regulatory 75
Nov 21, 2017: Array Biopharma Lead Plaintiff Deadline Alert: Faruqi & Faruqi Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The Firm 75
Product News 76
07/26/2018: Pierre Fabre Medicament receives CHMP’s positive opinion for Braftovi 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Array BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Array BioPharma Acquires Encorafenib from Novartis Pharma 13
Loxo Oncology Raises US$10 Million In Venture Financing 15
Array BioPharma Enters into Agreement with Pfizer 16
Amgen and Array BioPharma Enter into Agreement 17
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 18
Array BioPharma Enters into Agreement with Merck 19
Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 20
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 21
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 22
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 23
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 24
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 25
Ono Pharma Enters into Licensing Agreement with Array BioPharma 26
Mirati Therapeutics Exercises Option For Licensing Agreement With Array BioPharma 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 29
Loxo Oncology Amends Licensing Agreement With Array BioPharma 30
Array Biopharma Plans to Raise up to USD125 Million in Public Offering of Shares 32
Yarra Therapeutics Spins Out from Array BioPharma 33
Array BioPharma Raises USD258.7 Million in Public Offering of Shares 34
Array BioPharma Raises USD132.3 Million in Public Offering of Shares 36
Array Biopharma Announces Public Offering Of Shares For US$75 Million 38
Array BioPharma Completes Underwriters' Exercise Of Over-Allotment Option For US$10 Million 39
Array BioPharma Completes Public Offering Of Common Stock For US$60 Million 41
Array BioPharma Raises USD10 Million in Private Placement of 5% Notes Due 2017 43
Array BioPharma Completes Public Offering Of Notes Due 2020 For US$132 Million 44
Accuratus Lab Services Acquires CMC Operation from Array BioPharma 46
Array BioPharma Inc, Key Competitors 47
Array BioPharma Inc, Key Employees 48
Array BioPharma Inc, Other Locations 49

List of Figures
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Array BioPharma Inc (ARRY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RPC Group PLC:企業の戦略・SWOT・財務情報
    RPC Group PLC - Strategy, SWOT and Corporate Finance Report Summary RPC Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Driver Group Plc (DRV):企業の財務・戦略的SWOT分析
    Driver Group Plc (DRV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • HSC Technology Group Ltd (HSC):企業の財務・戦略的SWOT分析
    HSC Technology Group Ltd (HSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Beiersdorf AG (BEI):企業の財務・戦略的SWOT分析
    Beiersdorf AG (BEI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Swissport Tanzania Limited:企業の戦略・SWOT・財務分析
    Swissport Tanzania Limited - Strategy, SWOT and Corporate Finance Report Summary Swissport Tanzania Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Sime Darby Berhad:戦略・SWOT・企業財務分析
    Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report Summary Sime Darby Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ARCA biopharma Inc (ABIO):企業の財務・戦略的SWOT分析
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Tabcorp Holdings Limited (TAH):企業の財務・戦略的SWOT分析
    Tabcorp Holdings Limited (TAH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Del Frisco’s Restaurant Group, Inc.:企業の戦略・SWOT・財務情報
    Del Frisco’s Restaurant Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Del Frisco’s Restaurant Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Department of Defense Education Activity:企業の戦略的SWOT分析
    Department of Defense Education Activity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Fujikura Ltd.:企業の戦略・SWOT・財務情報
    Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Kuros Biosciences AG (KURN):企業の製品パイプライン分析
    Summary Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as we …
  • Enbridge Inc (ENB):石油・ガス:M&Aディール及び事業提携情報
    Summary Enbridge Inc (Enbridge) is an integrated energy company. It carries out natural gas gathering, processing, transmission and distribution; transportation of crude oil; and marketing of petroleum products. The company also involved in power generation and transmission and has interests in rene …
  • Allergan Plc (AGN)-医療機器分野:企業M&A・提携分析
    Summary Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology …
  • New Zealand Post Limited:企業の戦略的SWOT分析
    New Zealand Post Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Nuvia Ltd:企業の戦略的SWOT分析
    Nuvia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • RainDance Technologies Inc-製薬・医療分野:企業M&A・提携分析
    Summary RainDance Technologies Inc (RDT) is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA. It also offers RainDrop Plus digital PCR s …
  • The British United Provident Association Ltd:企業の戦略的SWOT分析
    The British United Provident Association Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Sanara MedTech Inc (WNDM):企業の財務・戦略的SWOT分析
    Summary Sanara MedTech Inc (Sanara MedTech), formerly WNDM Medical Inc is a distributor of biotechnology products to hospitals, physicians, and clinics. The company offers its patented product CellerateRX in powder and gel forms, and hemaquell resorbable bone wax that controls bone bleeding. Its pro …
  • Emerson Radio Corporation (MSN):企業の財務・戦略的SWOT分析
    Emerson Radio Corporation (MSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆